Tapentadol Aqueous Oral Formulation Preservative Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing solid oral dosage forms of tapentadol are not satisfactory in terms of stability and preservative-related side effects, with a need for improved formulations that minimize chemical and physical degradation and microbial contamination without relying on harsh preservatives.
Innovation Solution
Development of aqueous pharmaceutical compositions with high water content and optimized pH and preservative levels, where tapentadol exhibits preservative properties, allowing for reduced or eliminated use of traditional preservatives, and incorporating suitable solvents and buffers to maintain stability and antimicrobial activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional preservatives are used in aqueous formulations, then microbial contamination is controlled, but preservative-related side effects and chemical stability deteriorate
Solution Approach 1:
The patent removes traditional preservatives from the formulation entirely, relying instead on the intrinsic preservative properties of tapentadol at optimized concentrations (above 10 mg/mL). This extraction of harmful preservative substances eliminates preservative-related side effects while maintaining microbial control through the active ingredient itself.
Solution Approach 2:
Tapentadol serves dual functions as both the active analgesic ingredient and the preservative agent. At concentrations above 10 mg/mL, tapentadol exhibits inherent antimicrobial activity that protects the aqueous formulation without requiring external preservatives, allowing the main ingredient to service the preservative function.
2Ease of operation
If aqueous formulations are used instead of solid dosage forms, then ease of administration and patient compliance improve, but chemical and physical stability deteriorate
Solution Approach 1:
The patent optimizes critical parameters including pH (adjusted to specific ranges to minimize degradation), temperature (storage recommendations), and tapentadol concentration (above 10 mg/mL for preservative effect). These parameter changes stabilize the aqueous formulation chemically and physically while maintaining its liquid state for ease of administration.
Solution Approach 2:
The formulation is pre-stabilized during manufacturing with optimized pH adjustment and controlled ingredient interactions to prevent degradation before use. Antioxidants and chelating agents are incorporated in advance to prevent oxidation and metal-catalyzed degradation, ensuring stability is established before the product reaches the patient.
3Stability of the object's composition
If antioxidants and chelating agents are added to prevent oxidation, then chemical stability improves, but formulation complexity and manufacturing cost increase
Solution Approach 1:
Antioxidants (such as ascorbic acid, tocopherols) and chelating agents (such as EDTA) are introduced as intermediary substances that mediate between the tapentadol and oxygen/metal ions. These intermediaries prevent direct oxidation of tapentadol by reacting with free radicals or sequestering metal catalysts, thereby protecting the active ingredient without requiring fundamental changes to the formulation structure.
Data Source
AI summary
An aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof and being adapted for oral administration. The composition has excellent storage stability without relying on the presence of high amounts of preservatives.